Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96,871 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of the efficacy and feasibility of concurrent weekly docetaxel-nedaplatin and hypo-fractionated radiotherapy in atypical histologic subtypes of primary and metastatic mediastinal malignancies.
Meng F, Ai X, Wang B, Zhou Y, Li S, Wang D, Liu F, Chen N, Zhou R, Guo J, Huang X, Yin S, Qiu B, Liu H. Meng F, et al. Among authors: liu h, liu f. Front Oncol. 2022 Oct 7;12:974394. doi: 10.3389/fonc.2022.974394. eCollection 2022. Front Oncol. 2022. PMID: 36276120 Free PMC article.
Real-world treatment and outcome patterns of patients with mantle cell lymphoma in China: A large, multicenter retrospective analysis.
Yang P, Cai QQ, Zhang W, Liu SZ, Liu H, Sun XH, Dong YJ, Xiao XB, Wang JW, Li ZL, Huang WR, Li LH, Bao HZ, Yang W, Wang YL, Wang SY, He J, Li XL, Liu AC, Jing HM. Yang P, et al. Among authors: liu ac, liu h, liu sz. Cancer Med. 2023 Jun;12(12):13204-13216. doi: 10.1002/cam4.6009. Epub 2023 May 6. Cancer Med. 2023. PMID: 37148540 Free PMC article.
Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
Ling Y, Xuan L, Xu N, Huang F, Fan Z, Guo Z, Xu X, Liu H, Lin R, Yu S, Zhang H, Jin H, Wu M, Liu C, Liang X, Ou R, Zhang Y, Liu X, Qu H, Zhai X, Sun J, Zhao Y, Liu Q. Ling Y, et al. Among authors: liu h, liu x, liu c, liu q. J Clin Oncol. 2023 Oct 10;41(29):4632-4642. doi: 10.1200/JCO.23.00101. Epub 2023 Jun 19. J Clin Oncol. 2023. PMID: 37335960 Clinical Trial.
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, Zhang H, Mehta-Shah N, Ding K, Liu Y, Li Z, Zhang L, Zheng M, Jin J, Yang H, Shuang Y, Yoon DH, Gao S, Li W, Zhai Z, Zou L, Xi Y, Koh Y, Li F, Prince M, Zhou H, Lin L, Liu H, Allen P, Roncolato F, Yang Z, Kim WS, Zhu J. Song Y, et al. Among authors: liu y, liu h. Lancet Oncol. 2024 Jan;25(1):117-125. doi: 10.1016/S1470-2045(23)00589-2. Epub 2023 Dec 9. Lancet Oncol. 2024. PMID: 38092009 Clinical Trial.
96,871 results
You have reached the last available page of results. Please see the User Guide for more information.